Literature DB >> 3134756

Long-term follow-up of the first successful bone marrow transplantation in Gaucher disease.

O Ringdén1, C G Groth, A Erikson, L Bäckman, S Granqvist, J E Månsson, L Svennerholm.   

Abstract

A 9-year-old girl with juvenile Gaucher disease underwent splenectomy and allogeneic bone marrow transplantation. Her HLA-identical brother with normal cerebroside-beta-glucosidase activity served as donor. One month after transplantation, cerebroside-beta-glucosidase activity in the lymphocytes were normal. Plasma glucosylceramide normalized already after splenectomy and further decreased after marrow transplantation. Glucosylceramide in the erythrocytes was normal around a year after transplantation. The enlarged liver normalized in size by 2 years. Gaucher cells were still present in the bone marrow 1 year after transplantation but had completely disappeared at 3 years. The patient has grown 29 cm during the 5 years that have passed after transplantation compared to 1 cm/year during 3 years before. The patient has a slight obstructive ventilatory impairment, and chest deformities have appeared. Wechsler intelligence scale performance has slowly decreased after transplantation. This may be caused by continued neuronal storage of glucosylceramide. Otherwise, this patient is active and healthy 5 years after bone marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3134756     DOI: 10.1097/00007890-198807000-00011

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  16 in total

1.  Glucocerebrosidase level in the cerebrospinal fluid during enzyme replacement therapy--unsuccessful treatment of the neurological abnormality in type 2 Gaucher disease.

Authors:  Makoto Migita; Hisamitsu Hamada; Juri Fujimura; Atsushi Watanabe; Takashi Shimada; Yoshitaka Fukunaga
Journal:  Eur J Pediatr       Date:  2003-04-23       Impact factor: 3.183

Review 2.  Gene therapy.

Authors:  S M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

3.  Long-term in vivo expression of the human glucocerebrosidase gene in nonhuman primates after CD34+ hematopoietic cell transduction with cell-free retroviral vector preparations.

Authors:  L C Xu; S Karlsson; E R Byrne; S Kluepfel-Stahl; S W Kessler; B A Agricola; S Sellers; M Kirby; C E Dunbar; R O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

4.  Production of human glucocerebrosidase in mice after retroviral gene transfer into multipotential hematopoietic progenitor cells.

Authors:  P H Correll; J K Fink; R O Brady; L K Perry; S Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

Review 5.  Hematopoietic stem cell transplantation for Gaucher disease.

Authors:  Usha R Somaraju; Krishna Tadepalli
Journal:  Cochrane Database Syst Rev       Date:  2017-10-18

6.  Elective subtotal splenectomy. Indications and results in 33 patients.

Authors:  P C Guzzetta; E J Ruley; H F Merrick; C Verderese; N Barton
Journal:  Ann Surg       Date:  1990-01       Impact factor: 12.969

Review 7.  Alglucerase. A review of its therapeutic use in Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

8.  Retroviral-mediated transfer of the human glucocerebrosidase gene into cultured Gaucher bone marrow.

Authors:  J A Nolta; X J Yu; I Bahner; D B Kohn
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

9.  Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector.

Authors:  T Ohashi; S Boggs; P Robbins; A Bahnson; K Patrene; F S Wei; J F Wei; J Li; L Lucht; Y Fei
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

10.  Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

Authors:  Deborah Elstein; Ari Zimran
Journal:  Biologics       Date:  2009-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.